| abstract |
Improved antisense oligonucleotide agents of formula (I) are disclosed for the treatment of pathogenic gram-negative bacterial infections. The said agents utilise an antibiotic-assisted translocation (AAT) platform to improve influx into bacterial cells through enhanced permeability, providing improved intracellular exposure of the antisense agent and superior treatment of the infection. The said agent takes the form of an acyl fragment of an N-acylmuramic acid or 1,6-anhydro-N-acylmuramic acid (SUGAR) which is conjugated to said oligonucleotide (ANTISENSE) via a linker as defined therein and L2, R1, R2, R3, R4, R5, R6 are each as defined therein and m is 0 or 1, n is 0-4, p is 0 or 1 and q is 0 or 1 or any pharmaceutically acceptable salt thereof. |